Toll-Like Receptor 4 Engagement Drives Differentiation of Human and Murine Dendritic Cells from a Pro- into an Anti-Inflammatory Mode

PLoS ONE

Volumn 8, Issue 2, 2013, Pages

  Luger, Romana ^a   Valookaran, Sneha ^a   Knapp, Natalie ^a   Vizzardelli, Caterina ^a   Dohnal, Alexander M ^a   Felzmann, Thomas ^a,b  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b Activartis Biotech GmbH   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 2 RECEPTOR ALPHA; TOLL LIKE RECEPTOR 4; TRANSCRIPTION FACTOR FOXP3;

ANIMAL CELL; ARTICLE; CELL DIFFERENTIATION; CELL PROLIFERATION; CONTROLLED STUDY; CYTOKINE RELEASE; DENDRITIC CELL; FLOW CYTOMETRY; HELPER CELL; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PHENOTYPE; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REGULATORY T LYMPHOCYTE; UPREGULATION; WESTERN BLOTTING;

ANIMALS; CELL DIFFERENTIATION; CYTOKINES; DENDRITIC CELLS; HUMANS; INFLAMMATION; MICE; TOLL-LIKE RECEPTOR 4;

EID: 84873629173     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0054879     Document Type: Article

References (51)

1. Steinman RM, Hemmi H, (2006) Dendritic cells: translating innate to adaptive immunity. Curr Top Microbiol Immunol 311: 17-58.
2. Heath WR, Carbone FR, (2009) Dendritic cell subsets in primary and secondary T cell responses at body surfaces. Nat Immunol 10: 1237-1244.
3. Sallusto F, Lanzavecchia A, (1994) Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. J Exp Med 179: 1109-1118.
4. Kaiser A, Bercovici N, Abastado JP, Nardin A, (2003) Naive CD8+ T cell recruitment and proliferation are dependent on stage of dendritic cell maturation. Eur J Immunol 33: 162-171.
5. Dohnal AM, Graffi S, Witt V, Eichstill C, Wagner D, et al. (2009) Comparative evaluation of techniques for the manufacturing of dendritic cell-based cancer vaccines. J Cell Mol Med 13: 125-135.
6. Matzinger P, (2002) The Danger Model: A Renewed Sense of Self. Science 296: 301-305.
7. Medzhitov R, Janeway CA Jr, (2002) Decoding the Patterns of Self and Nonself by the Innate Immune System. Science 296: 298-300.
8. Schreiber RD, Old LJ, Smyth MJ, (2011) Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 331: 1565-1570.
9. Jonuleit H, Kuhn U, Muller G, Steinbrink K, Paragnik L, et al. (1997) Pro-inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum-free conditions. Eur J Immunol 27: 3135-3142.
10. Cella M, Scheidegger D, Palmer-Lehmann K, Lane P, Lanzavecchia A, et al. (1996) Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation. J Exp Med 184: 747-752.
11. Schoenberger SP, Toes RE, van-der-Voort EI, Offringa R, Melief CJ, (1998) T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature 393: 480-483.
12. Ridge JP, Di-Rosa F, Matzinger P, (1998) A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell. Nature 393: 474-478.
13. Bennett SR, Carbone FR, Karamalis F, Flavell RA, Miller JF, et al. (1998) Help for cytotoxic-T-cell responses is mediated by CD40 signalling. Nature 393: 478-480.
14. Langenkamp A, Messi M, Lanzavecchia A, Sallusto F, (2000) Kinetics of dendritic cell activation: impact on priming of TH1, TH2 and nonpolarized T cells. Nat Immunol 1: 3116.
15. Felzmann T, Huttner KG, Breuer SK, Wimmer D, Ressmann G, et al. (2005) Semi-mature IL-12 secreting dendritic cells present exogenous antigen to trigger cytolytic immune responses. Cancer Immunol Immunother 54: 769-780.
16. Camporeale A, Boni A, Iezzi G, Degl'Innocenti E, Grioni M, et al. (2003) Critical impact of the kinetics of dendritic cells activation on the in vivo induction of tumor-specific T lymphocytes. Cancer Res 63: 3688-3694.
17. Hüttner KG, Breuer SK, Paul P, Majdic O, Heitger A, et al. (2005) Generation of potent anti-tumor immunity in mice by interleukin-12-secreting dendritic cells. Cancer Immunol Immunother 54: 67-77.
18. Saraiva M, O'Garra A (2010) The regulation of IL-10 production by immune cells. Nat Rev Immunol.
19. Askenasy N, Kaminitz A, Yarkoni S, (2008) Mechanisms of T regulatory cell function. Autoimmunity reviews 7: 370-375.
20. von Bergwelt-Baildon MS, Popov A, Saric T, Chemnitz J, Classen S, et al. (2006) CD25 and indoleamine 2,3-dioxygenase are up-regulated by prostaglandin E2 and expressed by tumor-associated dendritic cells in vivo: additional mechanisms of T-cell inhibition. Blood 108: 228-237.
21. Yu H, Kortylewski M, Pardoll D, (2007) Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nature reviews Immunology 7: 41-51.
22. Munn DH, Sharma MD, Lee JR, Jhaver KG, Johnson TS, et al. (2002) Potential regulatory function of human dendritic cells expressing indoleamine 2,3-dioxygenase. Science 297: 1867-1870.
23. Jurgens B, Hainz U, Fuchs D, Felzmann T, Heitger A, (2009) Interferon-gamma-triggered indoleamine 2,3-dioxygenase competence in human monocyte-derived dendritic cells induces regulatory activity in allogeneic T cells. Blood 114: 3235-3243.
24. Xu M, Mizoguchi I, Morishima N, Chiba Y, Mizuguchi J, et al. (2010) Regulation of antitumor immune responses by the IL-12 family cytokines, IL-12, IL-23, and IL-27. Clinical & developmental immunology 2010.
25. Dohnal AM, Witt V, Hugel H, Holter W, Gadner H, et al. (2007) Phase I study of tumor Ag-loaded IL-12 secreting semi-mature DC for the treatment of pediatric cancer. Cytotherapy 9: 755-770.
26. Driesen J, Popov A, Schultze JL, (2008) CD25 as an immune regulatory molecule expressed on myeloid dendritic cells. Immunobiology 213: 849-858.
27. Mailliard RB, Wankowicz-Kalinska A, Cai Q, Wesa A, Hilkens CM, et al. (2004) alpha-type-1 polarized dendritic cells: a novel immunization tool with optimized CTL-inducing activity. Cancer Res 64: 5934-5937.
28. Bousso P, (2008) T-cell activation by dendritic cells in the lymph node: lessons from the movies. Nature reviews Immunology 8: 675-684.
29. Gunzer M, Schafer A, Borgmann S, Grabbe S, Zanker KS, et al. (2000) Antigen presentation in extracellular matrix: interactions of T cells with dendritic cells are dynamic, short lived, and sequential. Immunity 13: 323-332.
30. Mempel TR, Henrickson SE, Von Andrian UH, (2004) T-cell priming by dendritic cells in lymph nodes occurs in three distinct phases. Nature 427: 154-159.
31. Mnasria K, Lagaraine C, Velge-Roussel F, Oueslati R, Lebranchu Y, et al. (2008) Anti-CD25 antibodies affect cytokine synthesis pattern of human dendritic cells and decrease their ability to prime allogeneic CD4+ T cells. J Leukoc Biol 84: 460-467.
32. Mitchell DA, Cui X, Schmittling RJ, Sanchez-Perez L, Snyder DJ, et al. (2011) Monoclonal antibody blockade of IL-2 receptor alpha during lymphopenia selectively depletes regulatory T cells in mice and humans. Blood 118: 3003-3012.
33. Wuest SC, Edwan JH, Martin JF, Han S, Perry JSA, et al. (2011) A role for interleukin-2 trans-presentation in dendritic cell-mediated T cell activation in humans, as revealed by daclizumab therapy. Nat Med 17: 604-609.
34. Yang ZZ, Grote DM, Ziesmer SC, Manske MK, Witzig TE, et al. (2011) Soluble IL-2Ralpha facilitates IL-2-mediated immune responses and predicts reduced survival in follicular B-cell non-Hodgkin lymphoma. Blood 118: 2809-2820.
35. Macatonia SE, Hsieh CS, Murphy KM, O'Garra A, (1993) Dendritic cells and macrophages are required for Th1 development of CD4+ T cells from alpha beta TCR transgenic mice: IL-12 substitution for macrophages to stimulate IFN-gamma production is IFN-gamma-dependent. Int Immunol 5: 1119-1128.
36. O'Garra A, Murphy KM, (2009) From IL-10 to IL-12: how pathogens and their products stimulate APCs to induce T(H)1 development. Nat Immunol 10: 929-932.
37. Corinti S, Albanesi C, la Sala A, Pastore S, Girolomoni G, (2001) Regulatory activity of autocrine IL-10 on dendritic cell functions. Journal of immunology 166: 4312-4318.
38. Zobywalski A, Javorovic M, Frankenberger B, Pohla H, Kremmer E, et al. (2007) Generation of clinical grade dendritic cells with capacity to produce biologically active IL-12p70. J Transl Med 5: 18.
39. Lee JJ, Foon KA, Mailliard RB, Muthuswamy R, Kalinski P, (2008) Type 1-polarized dendritic cells loaded with autologous tumor are a potent immunogen against chronic lymphocytic leukemia. J Leukoc Biol 84: 319-325.
40. Wieckowski E, Chatta GS, Mailliard RM, Gooding W, Palucka K, et al. (2011) Type-1 polarized dendritic cells loaded with apoptotic prostate cancer cells are potent inducers of CD8(+) T cells against prostate cancer cells and defined prostate cancer-specific epitopes. Prostate 71: 125-133.
41. Czerniecki BJ, Koski GK, Koldovsky U, Xu S, Cohen PA, et al. (2007) Targeting HER-2/neu in early breast cancer development using dendritic cells with staged interleukin-12 burst secretion. Cancer Res 67: 1842-1852.
42. Benencia F, Courreges MC, Coukos G, (2008) Whole tumor antigen vaccination using dendritic cells: comparison of RNA electroporation and pulsing with UV-irradiated tumor cells. J Transl Med 6: 21.
43. Han TH, Jin P, Ren J, Slezak S, Marincola FM, et al. (2009) Evaluation of 3 clinical dendritic cell maturation protocols containing lipopolysaccharide and interferon-gamma. J Immunother 32: 399-407.
44. Cobb A, Roberts LK, Palucka AK, Mead H, Montes M, et al. (2011) Development of a HIV-1 lipopeptide antigen pulsed therapeutic dendritic cell vaccine. J Immunol Methods 365: 27-37.
45. Boullart AC, Aarntzen EH, Verdijk P, Jacobs JF, Schuurhuis DH, et al. (2008) Maturation of monocyte-derived dendritic cells with Toll-like receptor 3 and 7/8 ligands combined with prostaglandin E2 results in high interleukin-12 production and cell migration. Cancer Immunol Immunother 57: 1589-1597.
46. Roses RE, Xu S, Xu M, Koldovsky U, Koski G, et al. (2008) Differential production of IL-23 and IL-12 by myeloid-derived dendritic cells in response to TLR agonists. J Immunol 181: 5120-5127.
47. Kalinski P, Hilkens CM, Wierenga EA, Kapsenberg ML, (1999) T-cell priming by type-1 and type-2 polarized dendritic cells: the concept of a third signal. Immunol Today 20: 561-567.
48. Traxlmayr MW, Wesch D, Dohnal AM, Funovics P, Fischer MB, et al. (2010) Immune suppression by gammadelta T-cells as a potential regulatory mechanism after cancer vaccination with IL-12 secreting dendritic cells. J Immunother 33: 40-52.
49. Felzmann T, Witt V, Wimmer D, Ressmann G, Wagner D, et al. (2003) Monocyte enrichment from leukapharesis products for the generation of DCs by plastic adherence, or by positive or negative selection. Cytotherapy 5: 391-398.
50. Battye FL, Light A, Tarlinton DM, (2000) Single cell sorting and cloning. Journal of immunological methods 243: 25-32.
51. Dohnal AM, Luger R, Paul P, Fuchs D, Felzmann T, (2009) CD40 ligation restores type 1 polarizing capacity in TLR4-activated dendritic cells that have ceased interleukin-12 expression. J Cell Mol Med 13: 1741-1750.